CASA2019 - SEPTEMBER 4-6, 2019 PORTOLA HOTEL & SPA MONTEREY, CA - California Ambulatory Surgery ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
CASA
ANNUAL CONFERENCE
& EXHIBITS
2019
SEPTEMBER 4-6, 2019
PORTOLA HOTEL & SPA
MONTEREY, CA
CASA President’s Message On behalf of CASA, I would like to officially welcome you to our 2019 annual conference. This will be our 32nd annual meeting. My term as president is ending, and I can assure you the CASA Board has never been more active and is diligently working in several areas to better serve California ASCs. As California’s new Governor works toward his legacy, healthcare will be a priority in California. CASA is working with our elected officials to assure they have a profound understanding of how California ASCs provide significant cost savings, innovation and quality outcomes. As you well realize, ASCs are not without their challenges, and I am sure you have dealt with emerging concerns on a daily basis. We will highlight these challenges and strategies to address utilizing the VUCA (volatility, uncertainty, complexity, ambiguity) principles. On Wednesday, our panel of distinguished experts will set the stage, and General George W. Casey, Jr., will provide us with a tactical approach to meet these challenges head-on. Our Thursday, Keynote speaker John Izzo, Ph.D., will motivate us to take on these responsibilities and be the agent of change. Following the morning sessions, the conference committee has organized a diverse program of breakout sessions, and we are fortunate to have the breadth of expert speakers to share their knowledge with us. The CASA Board is continually striving to address the changing needs of our members and effectively move the CASA organization forward. I will be highlighting the Board’s activities during my presentation on Thursday morning, at 8:00 a.m. I am excited to be unveiling some new CASA benefits and opportunities to help you run your center. This informative business session is a great opportunity to see all the areas CASA is working for your ASC’s success. Friday’s sessions will bring us a panel on using quality metrics and marketing your ASC and an important session of staff engagement with Greg Miller, Ph.D. We are grateful for the open dialogue CASA has with our regulators. Friday’s closing session will bring us a wide variety of experts representing the Medical Board of California, California Department of Public Health, Centers for Medicare and Medicaid Services and accreditation agencies. We will take some time to relax and enjoy a bit of Monterey history for the Thursday Evening Rustic Roundup. This event is off-site at the historic Barnes, just a short walk up the road. This is a great time to network while enjoying good music, food and games. Our sponsors and vendors are critical to the success of our meetings. Please take the opportunity to thank them throughout the meeting, and make sure to maximize your time in the exhibit hall. The diversity of exhibitors will allow you to investigate the latest in technology, products, and services affecting our industry. As always, we have included a fun game to enhance the experience, and who doesn’t like an opportunity to win cash and prizes? In closing, I want to assure you that the CASA Board and administrative team are here to help you and your ASC. Your input is critical for our success. Be sure to take full advantage of the conference app and complete your evaluations for education credit. Your feedback will help us with the planning of future meetings and better serve you in all areas. The CASA Board and staff want to get to know you. So please take this opportunity to say hello; we welcome the opportunity to learn more about you and your center. Enjoy the meeting and networking with peers, Deborah Miller CASA President
CASA THANKS OUR PLATINUM SPONSOR
Get the business and operation
solutions you need. Stat.
From the business office to the surgical suite, McKesson Medical-Surgical
“Prior to Implant Manager we would
delivers inventory management solutions to help you increase efficiency, spend hours figuring out where a lens
save time and reduce costs so you can focus on patient care. went, which doctor implanted what
lens and which lens was associated
• McKesson Implant Manager – automated IOL tracking with a specific patient. I would have
reduces risk of inventory discrepancies to spend hours looking at expiration
dates of over 4,500 lenses. Now it is a
• McKesson CSOSManagerSM - order controlled substances, simple click and complete.”
but avoid delays and eliminate manual paperwork - Anna Conley, Purchasing Agent
Cincinnati Eye Institute
Visit us online to learn more about how we
can help you manage your inventory and more.
mms.mckesson.com/asc | 866.MCK.ANSWer (866.625.2679)
© 2018 McKesson Medical-Surgical Inc.
CASA’s Mission Statement
CASA’s Mission is to serve as a proactive leader in the California
ambulatory surgery industry.
Vision Statement
The California Ambulatory Surgery Association will increase surgical care quality and value through communication,
education and advocacy. By:
• Dramatically increasing membership from both multi-specialty and single specialty centers
• Effectively partnering with organizations with similar goals and objectives
• Leading/supporting critical legislative and regulatory reform
• Utilizing/leveraging information and communication technologies
• Electing a motivated and committed Board of Directors
• Becoming more influential in the industry, the community and the legislative branches
Member Code of Conduct
The California Ambulatory Surgery Association (“CASA”) and each of its members agree to adopt and implement
policies to promote ethical management in the ambulatory surgery industry. Members shall promote the advancement
of ambulatory surgery technology and methods, encourage educational activities demonstrating the benefits of
ambulatory surgery, promote the efficient, safe and effective utilization of medical care resources and operate facilities
in a fiscally responsible manner benefiting and protecting the general public.
As part of these ethical obligations, each member agrees to observe, to the extent applicable to a facility, ethical
business practices, including but not limited to:
A member facility should not charge or collect an illegal or excessive fee. A fee is considered excessive when after a
review of the facts a person knowledgeable as to current charges made by facilities would be left with a definite and
firm conviction that the fee is in excess of a reasonable fee. Factors to be considered as guides in determining the
reasonableness of a fee include the following:
(1) The difficulty and/or uniqueness of the services performed and the time, skill, and experience required
(2) The fee customarily charged in the locality for similar care by facilities that are committed to providing
safe and effective care in an efficient and fiscally responsible manner benefitting and protecting the
general public.
(3) The amount of the charges involved.
(4) The quality of performance.
(5) The experience, reputation, and ability of the facility in performing the kind of services involved.
The above statement regarding fees is modeled from Opinion 6.05 (as modified in 1994) of the American Medical
Association Code of Medical Ethics.
A member facility agrees to be transparent and lawful in its billing and collection practices. Factors to be considered as
guides in determining transparency and lawfulness include the following:
(1) Timely pre and post-treatment notifications of the patient (or parent or legal conservator if the patient
is a minor, or an adult with a legal conservatorship) of anticipated and real charges, and expectations
regarding the financial responsibilities of the patient, parent or legal conservator, and of any third party
payer to be billed.
(2) Avoidance of unlawful payments or other improper inducements for referral of patients to the facility.
(amended 2013)
Delivering the highest standard of care and
quality to our highest priority—our patients.
AMSURG is committed to offering the safest, highest-quality patient experience.
Each of our centers:
Are Medicare-approved
Undergo voluntary accreditation by the Accreditation Association for
Ambulatory Health Care (AAAHC) or the Joint Commission
Voluntarily comply with OAS CAHPS (Outpatient and Ambulatory Surgery
Consumer Assessment of Healthcare Providers and Systems)
Our centers’ Governing Boards and medical staff meet quarterly to continually
ensure a patient-centric culture. Providing every patient personalized and
compassionate care is at the center of all we do.
Learn more at AMSURG.com
Proud CASA Sponsor
Program at a glance
WEDNESDAY, SEPTEMBER 4, 2019
CONFERENCE BEGINS ON WEDNESDAY
10:00 AM to 5:00 PM Conference Registration
3:00 PM to 5:00 PM ASCs in a VUCA World (Volatility, Uncertainty, Complexity, and Ambiguity)
5:00 PM to 7:00 PM Welcome Reception in Exhibit Hall
THURSDAY, SEPTEMBER 5, 2019
7:00 AM to 8:00 AM Conference Registration
8:00 AM to 8:30 AM CASA Business Meeting
8:30 AM to 9:30 AM California and National Legislative Update
9:30 AM to 9:45 AM Break
9:45 AM to 11:00 AM KEYNOTE: John Izzo - Leadership Expert & Author
100% Responsibility - 0% Excuses: Creating a Culture of Ownership
11:00 AM to 1:00 PM Lunch with Exhibitors
1:00 PM to 2:00 PM Track 1 - Expanding Revenue in an ASC to Increase Profits FINANCIAL
Track 2 - The Difficult Employee and a Proactive Approach HR
from a Leadership Perspective
Track 3 - Surgical Smoke in the Clinical Environment CLINICAL
Track 4 - Quality, Safety & the Patient Experience QUALITY
How Improving your Facility’s Culture and
Employee Engagement Drives These Three Areas
2:05 PM to 3:05 PM Track 1 - Improving Sales Skills to Grow Case Volume FINANCIAL
Track 2 - The Top Mistakes When Dealing with the Injured Worker HR
Track 3 - Communication in the Clinical Setting CLINICAL
Track 4 - Developing a Reliable On-Boarding Program QUALITY
for Registry Staff & Per Diem Nurses
3:05 PM to 4:00 PM Break with Exhibitors
4:00 PM to 5:00 PM Track 1 - Best Practices for Revenue Cycle Management FINANCIAL
Track 2 - Incorporating Social Media for ASC Success HR
Track 3 - High Caliber Clinicians/High Acuity Patients CLINICAL
and Screening for Both
Track 4 - Training & Developing Your Safety Officer QUALITY
5:05 PM to 6:05 PM Accreditation 4-1-1
7:00 PM to 9:30 PM Thursday Special Event
FRIDAY, SEPTEMBER 6, 2019
8:00 AM to 9:00 AM Quality and Safety in the ASC - Telling the ASC Story
9:00 AM to 10:00 AM Gaining the Edge with Staff Engagement
10:00 AM to 10:20 AM Break
10:20 AM to 12:00 PM Regulatory Update Panel
EXHIBITORS
3M Healthcare................................................................ 9
AAAHC......................................................................... 20
With sincere appreciation, we thank our
Sponsors & Exhibitors
AcelRx Pharmaceuticals, Inc......................................... 93
Advocare+.................................................................... 68
Alsco............................................................................. 79
AORN........................................................................... 87
ARC Medical................................................................. 37
ASC Connect.............................................................. TT3
ASC Pharmacist Consultants........................................ 48
Avante Health Solutions............................................... 49
BD/CAREFUSION/BARD.............................................. 28
PLATINUM SPONSOR
Boston Scientific........................................................... 61
Bryton Corporation....................................................... 81
Cadmet, Inc.................................................................. 22
California Cancer Registry.............................................. 7
Cardinal Health............................................................. 60
Cardio Surgical Partners .............................................. 44
CAREDirect................................................................... 77
Casetabs....................................................................... 14
Clariti Health................................................................. 47
CONFERENCE EVENT
Clorox........................................................................... 71
Coding Network (The).................................................. 42
Credit Consulting Services........................................... 41
Crosstex........................................................................ 72
Eagle Pharmaceuticals.................................................. 55
ECG Management Consultants.................................... 76
SPONSORS SPONSORS
Echelon Medical Capital............................................... 31
eClinicalWorks.............................................................. 40 AMSURG
EH Butland Corp.......................................................... 10
Ellex iTrack...................................................................... 8 Ambulatory Systems Development
Envision Physician Services........................................... 19
Excellentia Advisory Group.......................................... 50
Getinge........................................................................ 16
Anthem Blue Cross
Global 1........................................................................ 86
Halyard Global Products Division................................... 6
ASC Connect, LLC
Henry Schein................................................................ 89
HST ASC Software........................................................ 12 Blue Shield of CA
Image Diagnostics........................................................ 92
ImageFIRST.................................................................. 96 Cigna
Inform Diagnostics....................................................... 85
Institute for Medical Quality......................................... 57
Intalere......................................................................... 26
Envision Physician Services
Inventory Optimization Solutions (IOS)........................ 15
IPG................................................................................ 84 HCA Healthcare
HealthNet of CA
James G. Parker Insurance Associates......................... 70
Key Surgical.................................................................. 65
LabCorp.......................................................................... 1
McKesson................................................................ 73.74 National Cardiovascular Partners
Medely.......................................................................... 63
Medical Products Resource.......................................... 38
MediMax Tech.............................................................. 25
Nossaman LLP
Medline Industries........................................................ 39
MedTek, Inc.................................................................. 32 Provation Medical
MedWest Surgical........................................................ 66
Merritt Healthcare Advisors.......................................... 94 SOMA Technology
Mizuho OSI................................................................... 56
Mobile Instrument Service & Repair............................. 21 Surgery Partners
Modernizing Medicine Gastroenterology.................... 78
MTBC........................................................................... 17
MultiMedical Systems................................................... 29
Sutter Health
Nanosonics, Inc.............................................................. 3
National Cardiovascular Partners............................... TT6 UnitedHealthcare
National Medical Billing Services................................. 83
Nuance Communications............................................. 35 United Surgical Partners
International
One Medical Passport.................................................. 62
OneSource Document Management Services............. 75
Pacira Biosciences, Inc.................................................. 30
ELITE SPONSORS
Parcus Medical............................................................. 91
Precision Medical Products..................................... 45.46
Prescott’s Inc................................................................. 67
Provation Medical....................................................... TT1
Provista......................................................................... 36
SCM Associates.............................................................. 5
Seattle Technology....................................................... 24
SI-BONE, Inc................................................................ 95
Silikal America.............................................................. 27
Simple PRM.................................................................. 23
Simplify ASC................................................................. 64
Smith & Nephew.......................................................... 18
Sodexo CTM................................................................. 58
SOMA Technology....................................................... 59
Sportstek Medical......................................................... 54
SurgeryLink, Inc............................................................ 34
Surgical Care Affiliates.................................................. 53
Surgical Information Systems....................................... 11
Surgical Notes.............................................................. 13
SurgLogs....................................................................... 80
Sutter Health.................................................................. 2
Sweet Dreams Anesthesia............................................ 52
The Alternative Source Medical................................... 69
The Joint Commission.................................................... 4
The SSI Group.............................................................. 33
United Medical Instruments, Inc................................. TT2
US WorldMeds............................................................. 82
WorkLogicHR................................................................ 88
Ziehm Imaging............................................................. 90
ZRG Medical................................................................. 51
Zulu Health................................................................... 43
Get patients back to the lives they love. Sutter-affiliated ambulatory surgery centers are leaders in implementing new technology and techniques, including the latest in total joint replacement surgeries. Join our team! We provide excellent career opportunities and are committed to promoting from within. Visit us at sutterhealth.org/surgery-center-division.
Speakers
KEYNOTE SPEAKER Missy Danforth I. Naya Kehayes
VP, Health Care Ratings Principal, ECG Management Consultants
Dr. John Izzo, Ph.D
The Leapfrog Group 1111 Third Ave. Ste. 2500
LEADERSHIP EXPERT/
1660 L Street NW, Ste. 308 Seattle, WA 98101
AUTHOR Washington, DC 20036 nkehayes@ecgmc.com
Vancouver, BC
mdanforth@leapfroggroup.org ASCs in a VUCA World
info@drjohnizzo.com
Quality and Safety in the ASC - Wednesday • 3:00 PM
100% Responsibility - Telling the ASC Story
0% Excuses: Creating a Culture Friday • 8:00 AM Kimberly Kirchmeyer
of Ownership Executive Director, Medical Board of CA
Thursday • 9:45 AM Tarin English 2005 Evergreen St.
Michael Bennett Assistant Director, Regulatory Compliance Sacramento, CA 95815
Medical Consultant Accreditation Association for Ambulatory kimberly.kirchmeyer@mbc.ca.gov
Licensing & Certification Program Health Care Regulatory Update
California Department of Public Health 5250 Old Orchard Rd, Ste. 200 Friday • 10:20 AM
850 Marina Bay Parkway Skokie, IL 60077
Building P, 1st Floor tenglish@aaahc.org Shea Lansberry, RN, MPA
Richmond, CA 94804-6403 Accreditation 411 - AAAHC Regional Clinical Director, Sutter Health
Regulatory Update Panel Thursday • 5:05 PM LansbeS@sutterhealth.org
Friday • 10:20 AM Training & Developing your
Tim Fuchs Safety Officer
Gen. George W. Casey, Jr. VP, Client Services Thursday • 4:00 PM
U.S Army (RET) National Medical Billing Services
Worldwide Speakers Group 7 Arnage Road Michael B. Larsen
99 Canal Center Plaza Ste. 100 St. Louis, MO 63005 Executive Director, MCSIG
Alexandria, VA 22314 tim.fuchs@nationalascbilling.com 76 Stephanie Dr.
ASCs in a VUCA World Best Practices for Salinas, CA 93901
Wednesday • 4:00 PM Revenue Cycle Management Quality and Safety in the ASC -
Thursday • 4:00 PM Telling the ASC Story
Lisa Cooper Friday • 8:00 AM
Principal, Advocare+ John J. Goehle, MBA, CASC, CPA
Lisa@advocareplus.com (moderator) Alethea Leandro-Farr
The Difficult Employee and Chief Operating Officer Safety & Loss Control Manager
a Proactive Approach from a Ambulatory Healthcare Strategies, LLC James G. Parker Insurance Associates
Leadership Perspective 2 Valley Meadow Dr. 1368 S. Main St., Ste A
Thursday • 1:00 PM Spencerport, NY 14559 Salinas, CA 93901
jgoehle@ah-strategies.com alethea@jgparker.com
Diana Dang Quality and Safety in the ASC - The Top Mistakes when Dealing with
PR Consultant, KP Public Affairs Telling the ASC Story the Injured Worker
621 Capitol Mall Ste. 1900 Friday • 8:00 AM Thursday • 2:05 PM
Sacramento, CA 95814
ddang@ka-pow.com Kelly Kapp, RN Scott Leggett
Incorporating Social Media Senior Director, Group Clinical Educator Co-Principal, Global 1 Ventures, LLC
for ASC Success Surgical Care Affiliates 6125 Paseo Del Norte, Ste. 210
Thursday • 4:00 PM 234 E. Colorado Blvd., Ste. 220 Carlsbad, CA 92011
Pasadena, CA 91101 scott@globaloneventures.com
kelly.kapp@scasurgery.com ASCs in a VUCA World
Communication in the Clinical Setting Wednesday • 3:00 PM
Thursday • 2:05 PMEasy on the eyes.
Literally.
AMBULA TO RY
SURGICAL
CENTER S
SOLUTION S
HSTeChart
When it comes to charting patients, we set the
standard. And now we’ve raised the bar with an
innovative, eyestrain-reducing design. More than
that, we’ve also added real-time data collection to
help your entire ASC operation run smoothly. And to
really add some efficiency to your workflows, we’ve
included concurrent charting which allows all your
clinicians to provide patient updates as they happen.
You truly have to see it to believe it.
For more information or to schedule a demo, visit hstpathways.com/echartSpeakers cont.
Jacqueline A. Lincer, Chief Amanda Olderog, MHA (moderator) Victoria Samper, MS
Region VI - Field Operations Branch Senior Director, Sg2 Vice President, Ambulatory Accreditation
California Department of Public Health 5250 Old Orchard Rd. Institute for Medical Quality
-L&C Skokie, IL 60077 180 Howard Street, Ste. 210
Regulatory Update aolderog@sg2.com San Francisco, CA 94105
Friday • 10:20 AM ASCs in a VUCA World victoria@imq.org
Wednesday • 3:00 PM Accreditation 411 - IMQ
Deborah L. Mack, RN, BSN, CASC, CAIP Thursday • 5:05 PM
Independent Healthcare Consultant Alden J. Parker
Ann Shimek, RN, BSN, MSN, CASC
11194 West Yucca Regional Managing Partner
Independent Consultant
Littleton, CO 80125 Fisher Phillips
5805 Braemer Drive
dmack1957@gmail.com 621 Capitol Mall, Ste. 1400
Plano, TX 75093
Training & Developing Sacramento, CA 95814
ashimekco@gmail.com
your Safety Officer aparker@fisherphillips.com
Quality, Safety & the Patient Experience -
Thursday • 4:00 PM The Difficult Employee and
How Improving your Facility’s Culture
a Proactive Approach from a
and Employee Engagement Drives These
Alison MacLeod Leadership Perspective
Three Areas
Partner, KP Public Affairs Thursday • 1:00 PM
Thursday • 1:00 PM
621 Capitol Mall Ste. 1900
Quality and Safety in the ASC -
Sacramento, CA 95814 Trey Parsons, RN
Telling the ASC Story
amacleod@ka-pow.com Sr. Vice President, Operations
Friday • 8:00 AM
Incorporating Social Media Ambulatory Systems Development, LLC
for ASC Success 850 E. Ocean Blvd., Unit 901 Mark Shirley, MS, CSP
Thursday • 4:00 PM Long Beach, CA 90802 Environmental Risk Consultant
tparsons@asd-asc.com Sutter Health
Greg Miller, Ph.D Legislative Update 2200 River Plaza Dr.
VP, Talent Management & Development Thursday • 8:30 AM Sacramento, CA 95833
Tenet Healthcare Expanding Revenue in an ASC ShirleM@sutterhealth.org
1445 Ross Ave., Ste. 1400 to Increase Profits Surgical Smoke in the
Dallas, TX 75202 Thursday • 1:00 PM Clinical Environment
greg1.miller@tenethealth.com Thursday • 1:00 PM
Gaining the Edge with Staff Engagement Bill Prentice
Friday • 9:00 AM Chief Executive Officer Stuart Simon, MD
Ambulatory Surgery Center Association Medical Director
Janet Miller, RN, MHA, CAIP 81012 Cameron St. United Surgical Partners International
Group Manager, Clinical Services Alexandria, VA 22314 4514 Lively Lane
Surgical Care Affiliates wprentice@ascassociation.org Dallas, TX 75220
5065 Nantucket Street Legislative Update ssimon@uspi.com
Roseville, CA 95747 Thursday • 8:30 AM High Caliber Clinicians/High Acuity
Janet.Miller@scasurgery.com Patients and Screening for Both
Developing a Reliable On-Boarding William Rutland Thursday • 4:00 PM
Program for Registry Staff & KP Public Affairs
Per diem Nurses 81012 Cameron St. Jason J. Strauss
Chief Operating Officer
Thursday • 2:05 PM 621 Capitol Mall Ste. 1900
Surgical Care Affiliates
Sacramento, CA 95814
569 Brookwood Village, Ste. 901
wrutland@ka-pow.com Birmingham, AL 35209
Legislative Update jason.strauss@scasurgery.com
Thursday • 8:30 AM ASCs in a VUCA World
Wednesday • 3:00 PMUnited Surgical Partners International specializes in the development
and operations of over 400 ambulatory
surgery centers, surgical hospitals, urgent care,
and imaging centers.
By leveraging the strength of joint venture partnerships and through a
strong commitment to clinical quality and excellence, USPI remains an
innovative leader within the industry.
Thank you to our outstanding administrators and
employees for living out our mission every day, and for
Every Day Giving Excellence!Speakers cont.
Devan Telken Darla VanPutten-Adams, MD John Wogec, MD
Director of Business Development Field Surveyor Exercise Coordinator
Surgery Partners The Joint Commission California Department of Public Health
310 Seven Springs Way, Ste. 500 One Renaissance Boulevard Emergency Preparedness Office
Brentwood, TN 37027 Oakbrook Terrace, IL 60181 John.Wogec@cdph.ca.gov
DTelken@surgerypartners.com Accreditation 411 – The Joint Commission Quality and Safety in the ASC -
Improving Sales Skills to Thursday • 5:05 PM Telling the ASC Story
Grow Case Volume Friday • 8:00 AM
Thursday • 2:05 PM Peggy Wellman (moderator)
Robert J. Zasa, MSHHA, FACMPE
Market President, USPI
Tara Vail President/CEO
200 N. Westlake Blvd., Suite 104
Chief Operating Officer Ambulatory Systems Development, LLC
HST ASC Software Westlake Village, CA 91362 21 Terraza Del Mar
3675 Mt. Diablo Blvd., Ste. 100 pwellman@uspi.com Dana Point, CA 92629
Lafayette. CA 94595 Regulatory Update rsaza@asd-asc.com
tara.vail@hstpathways.com Friday • 10:20 AM Expanding Revenue in an
ASCs in a VUCA World ASC to Increase Profits
Wednesday • 3:00 PM Thursday • 1:00 PM
CONTINUING HEALTH PROFESSIONS EDUCATION
This CME activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council
for Continuing Medical Education through the joint providership of The Institute for Medical Studies (IMS) and the California Ambulatory Surgery
Association. The Institute for Medical Studies is accredited by the ACCME to provide continuing medical education for physicians. The Institute for
Medical Studies designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credits™ for the full general conference, and 4 credits for the
Pre-Conference. *Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program is also provider approved by the California Board of Registered Nursing, provider number CEP 9344 for 11.75 contact hours for the
full General Conference and 4 contact hours for the Pre-Conference. This program is approved for 11.75 hours of AEU credits by BASC Provider
#7990 and 4 contact hours for the Pre-Conference.
Surgery centers only succeed when
physicians succeed.
Our commitment to our physician partners is the
cornerstone of our company’s growth and success.
Physicians at more than 260 surgery centers have chosen
AMSURG as their business partner.
We proudly partner with over 300 specialty physicians at
over 25 multi- and single-specialty centers in California.
Find out more at AMSURG.com
Proud CASA SponsorIntegrated
VISIT BOOTH #84 AT THE CASA TRADESHOW!
Surgical
Solutions
www.ipg.com
What we do
IPG works with commercial health plans to drive higher acuity procedures to ASCs
by ensuring the right reimbursement structure is in place and by taking on the
financial risk of the device to allow our participating ASCs to perform all procedure
types involving an implant.
How we achieve results for ASCs
We provide national We fund the cost We have an We manage the We take on
benchmarks to the of the device for our extensive network of payment and billing the patient
health plan relative partner ASCs. manufacturers across of the device. collection risk.
to appropriate all procedure types.
reimbursement rates.IPG partnering facilities perform on average 3x
more procedures than they did without IPG.
IMPLANT PROCEDURE Volume
FACILITY 13 5
7
FACILITY 12 9
10
FACILITY 11 3
8
FACILITY 10 7 WITHOUT IPG WITH IPG
16
FACILITY 9 3
19
FACILITY 8 2
30
FACILITY 7 8
34
FACILITY 6 4
40
FACILITY 5 3
57
FACILITY 4 4
76
FACILITY 3 11
111
FACILITY 2 3
145
FACILITY 1 36
137
0 20 40 60 80 100 120 140 160
Without IPG With IPG Illustrative Example
What That Means to Your ASC
• You get paid appropriately to do more volume and more profitable procedures.
• There is no cash outlay for the device and no costs associated with the program.
• You and your surgeons have access to newer technology and device options.
• The resource and financial burden for payment and billing of the device is removed.
• The impact of outstanding patient collections to your bottom line is removed.2019 SALARY SURVEY NOW AVAILABLE
SPECIAL OFFER ONLY FOR reg. $500
CONFERENCE ATTENDEES
Conference
See us at the CASA registration desk Attendee Price
$250
to purchase on-the-spot
Or order online at this discounted rate:
casurgery.org/surveypromo2019
FREE Exclusive Benchmarking
Our newly upgraded CASA benchmarking is FREE to members and includes areas mandated by
CMS and accreditation bodies.
This is the only benchmarking program that provides information specific to your California region.
Data Highlights include:
• Demographic & Ownership CASA Benchmarking is a critical component for
Structure progressive ASCs. Take advantage of this free
• Accreditation opportunity to improve your operations.
• Payor Mix
• Net Revenue Benchmarking Regions
• Days In AR by County
• Supplies as a % of Region 1
Net Revenue
Region 2
• Productive Hours Per Case
• Cancellation Rates Region 3
• Complications Colusa
Region 4
• Incidents Region 5
• Hospital Transfers
• Infection Rates
• Complaints
• Post-Operative
Normothermia
• Unplanned
Anterior Vitrectomies
C A L I F O R N I A
AMBULATORY SURGERY
A S S O C I AT I O N
Contact CASA Executive Director
Beth LaBouyer | 530.790.7990
info@casurgery.org | www.casurgery.orgLearn how non-opioid EXPAREL
BOOTH 30 improves recovery in the ASC
• Pain is the most common cause of PACU delays and the second most common reason
for hospital-based acute care admission after discharge from an ASC1,2
EXPAREL
provides long-lasting pain control3 AND…
Reduces or Enables faster
eliminates achievement of
opioid use3* recovery milestones4
*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.
ASC, ambulatory surgery center; PACU, post-anesthesia care unit.
Indication
EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical local analgesia
and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.
Safety and efficacy have not been established in other nerve blocks.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. Adverse reactions
reported with an incidence greater than or equal to 10% following EXPAREL administration via
infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence
greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus
nerve block were nausea, pyrexia, and constipation. If EXPAREL and other non-bupivacaine Scan me for
local anesthetics, including lidocaine, are administered at the same site, there may be an ASC outcomes
immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered data
to the same site 20 minutes after injecting lidocaine. EXPAREL is not recommended to be used
in the following patient population: patientsOther than bupivacaine as noted above, EXPAREL should not be admixed with circulatory depression may require administration of intravenous fluids and,
other drugs prior to administration. when appropriate, a vasopressor dictated by the clinical situation (such as
Water and Hypotonic Agents ephedrine to enhance myocardial contractile force).
Do not dilute EXPAREL with water or other hypotonic agents, as it will result in If not treated immediately, both convulsions and cardiovascular depression
Brief Summary disruption of the liposomal particles can result in hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. If
(For full prescribing information refer to package insert) cardiac arrest should occur, standard cardiopulmonary resuscitative measures
USE IN SPECIFIC POPULATIONS
INDICATIONS AND USAGE should be instituted.
EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical Pregnancy
Endotracheal intubation, employing drugs and techniques familiar to the
local analgesia and as an interscalene brachial plexus nerve block to produce Risk Summary clinician, maybe indicated, after initial administration of oxygen by mask, if
postsurgical regional analgesia. There are no studies conducted with EXPAREL in pregnant women. In animal difficulty is encountered in the maintenance of a patent airway or if prolonged
Limitation of Use: Safety and efficacy has not been established in other nerve blocks. reproduction studies, embryo-fetal deaths were observed with subcutaneous ventilatory support (assisted or controlled) is indicated.
administration of bupivacaine to rabbits during organogenesis at a dose
CONTRAINDICATIONS equivalent to 1.6 times the maximum recommended human dose (MRHD) DOSAGE AND ADMINISTRATION
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. While of 266 mg. Subcutaneous administration of bupivacaine to rats from implanta- Important Dosage and Administration Information
EXPAREL has not been tested with this technique, the use of bupivacaine HCl tion through weaning produced decreased pup survival at a dose equivalent to • EXPAREL is intended for single-dose administration only.
with this technique has resulted in fetal bradycardia and death. 1.5 times the MRHD [see Data]. Based on animal data, advise pregnant women • Different formulations of bupivacaine are not bioequivalent even if the
WARNINGS AND PRECAUTIONS of the potential risks to a fetus. milligram strength is the same. Therefore, it is not possible to convert
Warnings and Precautions Specific for EXPAREL The background risk of major birth defects and miscarriage for the indicated dosing from any other formulations of bupivacaine to EXPAREL.
As there is a potential risk of severe life-threatening adverse effects population is unknown. However, the background risk in the U.S. general • DO NOT dilute EXPAREL with water for injection or other hypotonic
associated with the administration of bupivacaine, EXPAREL should be population of major birth defects is 2-4% and of miscarriage is 15-20% of agents, as it will result in disruption of the liposomal particles.
administered in a setting where trained personnel and equipment are available clinically recognized pregnancies. • Use suspensions of EXPAREL diluted with preservative-free normal
to promptly treat patients who show evidence of neurological or cardiac toxicity. Clinical Considerations (0.9%) saline for injection or lactated Ringer’s solution within 4 hours
Caution should be taken to avoid accidental intravascular injection of EXPAREL. Labor or Delivery of preparation in a syringe.
Convulsions and cardiac arrest have occurred following accidental intravascular Bupivacaine is contraindicated for obstetrical paracervical block anesthesia. • Do not administer EXPAREL if it is suspected that the vial has been
injection of bupivacaine and other amide-containing products. While EXPAREL has not been studied with this technique, the use of bupivacaine frozen or exposed to high temperature (greater than 40°C or 104°F) for
Avoid additional use of local anesthetics within 96 hours following administration for obstetrical paracervical block anesthesia has resulted in fetal bradycardia an extended period.
of EXPAREL. and death. • Inspect EXPAREL visually for particulate matter and discoloration prior
Bupivacaine can rapidly cross the placenta, and when used for epidural, caudal, to administration, whenever solution and container permit. Do not
EXPAREL has not been evaluated for the following uses and, therefore, is not administer EXPAREL if the product is discolored.
recommended for these types of analgesia or routes of administration. or pudendal block anesthesia, can cause varying degrees of maternal, fetal,
• epidural and neonatal toxicity. The incidence and degree of toxicity depend upon the Recommended Dosing in Adults
procedure performed, the type, and amount of drug used, and the technique Local Analgesia via Infiltration
• intrathecal of drug administration. Adverse reactions in the parturient, fetus, and neonate
• regional nerve blocks other than interscalene brachial plexus nerve block involve alterations of the central nervous system, peripheral vascular tone, and The recommended dose of EXPAREL for local infiltration in adults is up to a
• intravascular or intra-articular use cardiac function. maximum dose of 266mg (20 mL), and is based on the following factors:
EXPAREL has not been evaluated for use in the following patient population and, Data • Size of the surgical site
therefore, it is not recommended for administration to these groups. • Volume required to cover the area
Animal Data
• patients younger than 18 years old Bupivacaine hydrochloride was administered subcutaneously to rats and rabbits • Individual patient factors that may impact the safety of an amide local
• pregnant patients during the period of organogenesis (implantation to closure of the hard plate). anesthetic
The potential sensory and/or motor loss with EXPAREL is temporary and Rat doses were 4.4, 13.3, and 40 mg/kg/day (equivalent to 0.2, 0.5 and 1.5 times As general guidance in selecting the proper dosing, two examples of infiltration
varies in degree and duration depending on the site of injection and dosage the MRHD, respectively, based on the BSA comparisons and a 60 kg human dosing are provided:
administered and may last for up to 5 days as seen in clinical trials. weight) and rabbit doses were 1.3, 5.8, and 22.2 mg/kg/day (equivalent to 0.1, • In patients undergoing bunionectomy, a total of 106 mg (8 mL) of EXPAREL
ADVERSE REACTIONS 0.4 and 1.6 times the MRHD, respectively, based on the BSA comparisons and was administered with 7 mL infiltrated into the tissues surrounding the
a 60 kg human weight). No embryo-fetal effects were observed in rats at the osteotomy, and 1 mL infiltrated into the subcutaneous tissue.
Clinical Trial Experience doses tested with the high dose causing increased maternal lethality. An increase • In patients undergoing hemorrhoidectomy, a total of 266 mg (20 mL) of
Adverse Reactions Reported in Local Infiltration Clinical Studies in embryo-fetal deaths was observed in rabbits at the high dose in the absence EXPAREL was diluted with 10 mL of saline, for a total of 30 mL, divided
The safety of EXPAREL was evaluated in 10 randomized, double-blind, local of maternal toxicity. into six 5 mL aliquots, injected by visualizing the anal sphincter as a clock
administration into the surgical site clinical studies involving 823 patients Decreased pup survival was noted at 1.5 times the MRHD in a rat pre- and face and slowly infiltrating one aliquot to each of the even numbers to
undergoing various surgical procedures. Patients were administered a dose post-natal development study when pregnant animals were administered produce a field block.
ranging from 66 to 532 mg of EXPAREL. In these studies, the most common subcutaneous doses of 4.4, 13.3, and 40 mg/kg/day buprenorphine hydrochloride Regional Analgesia via Interscalene Brachial Plexus Nerve Block
adverse reactions (incidence greater than or equal to 10%) following EXPAREL (equivalent to 0.2, 0.5 and 1.5 times the MRHD, respectively, based on the BSA
administration were nausea, constipation, and vomiting. The common adverse The recommended dose of EXPAREL for interscalene brachial plexus
comparisons and a 60 kg human weight) from implantation through weaning nerve block in adults is 133 mg (10 mL), and is based upon one study of patients
reactions (incidence greater than or equal to 2% to less than 10%) following (during pregnancy and lactation).
EXPAREL administration were pyrexia, dizziness, edema peripheral, anemia, undergoing either total shoulder arthroplasty or rotator cuff repair.
hypotension, pruritus, tachycardia, headache, insomnia, anemia postoperative, Lactation Compatibility Considerations
muscle spasms, hemorrhagic anemia, back pain, somnolence, and procedural pain. Risk Summary Admixing EXPAREL with drugs other than bupivacaine HCl prior to administra-
Adverse Reactions Reported in Nerve Block Clinical Studies Limited published literature reports that bupivacaine and its metabolite, tion is not recommended.
The safety of EXPAREL was evaluated in four randomized, double-blind, placebo- pipecoloxylidide, are present in human milk at low levels. There is no available • Non-bupivacaine based local anesthetics, including lidocaine, may cause
controlled nerve block clinical studies involving 469 patients undergoing various information on effects of the drug in the breastfed infant or effects of the drug an immediate release of bupivacaine from EXPAREL if administered
surgical procedures. Patients were administered a dose of either 133 or 266 mg on milk production. The developmental and health benefits of breastfeeding together locally. The administration of EXPAREL may follow the
of EXPAREL. In these studies, the most common adverse reactions (incidence should be considered along with the mother’s clinical need for EXPAREL and administration of lidocaine after a delay of 20 minutes or more.
greater than or equal to 10%) following EXPAREL administration were nausea, any potential adverse effects on the breastfed infant from EXPAREL or from the • Bupivacaine HCl administered together with EXPAREL may impact the
pyrexia, and constipation. underlying maternal condition. pharmacokinetic and/or physicochemical properties of EXPAREL, and
The common adverse reactions (incidence greater than or equal to 2% to less Pediatric Use this effect is concentration dependent. Therefore, bupivacaine HCl and
than 10%) following EXPAREL administration as a nerve block were muscle Safety and effectiveness in pediatric patients have not been established. EXPAREL may be administered simultaneously in the same syringe, and
twitching, dysgeusia, urinary retention, fatigue, headache, confusional state, Geriatric Use bupivacaine HCl may be injected immediately before EXPAREL as long as
hypotension, hypertension, hypoesthesia oral, pruritus generalized, hyperhid- Of the total number of patients in the EXPAREL local infiltration clinical studies the ratio of the milligram dose of bupivacaine HCl solution to EXPAREL
rosis, tachycardia, sinus tachycardia, anxiety, fall, body temperature increased, (N=823), 171 patients were greater than or equal to 65 years of age and does not exceed 1:2.
edema peripheral, sensory loss, hepatic enzyme increased, hiccups, hypoxia, 47 patients were greater than or equal to 75 years of age. Of the total number The toxic effects of these drugs are additive and their administration
post-procedural hematoma. of patients in the EXPAREL nerve block clinical studies (N=531), 241 patients should be used with caution including monitoring for neurologic and
Postmarketing Experience were greater than or equal to 65 years of age and 60 patients were greater than cardiovascular effects related to local anesthetic systemic toxicity.
These adverse reactions are consistent with those observed in clinical studies or equal to 75 years of age. No overall differences in safety or effectiveness • When a topical antiseptic such as povidone iodine (e.g., Betadine®)
and most commonly involve the following system organ classes (SOCs): Injury, were observed between these patients and younger patients. Clinical experience is applied, the site should be allowed to dry before EXPAREL is
Poisoning, and Procedural Complications (e.g., drug-drug interaction, with EXPAREL has not identified differences in efficacy or safety between elderly administered into the surgical site. EXPAREL should not be allowed to
procedural pain), Nervous System Disorders (e.g., palsy, seizure), General and younger patients, but greater sensitivity of some older individuals cannot come into contact with antiseptics such as povidone iodine in solution.
Disorders And Administration Site Conditions (e.g., lack of efficacy, pain), be ruled out. Studies conducted with EXPAREL demonstrated that the most common
Skin and Subcutaneous Tissue Disorders (e.g., erythema, rash), and Cardiac Hepatic Impairment implantable materials (polypropylene, PTFE, silicone, stainless steel, and
Disorders (e.g., bradycardia, cardiac arrest). Amide-type local anesthetics, such as bupivacaine, are metabolized by the liver. titanium) are not affected by the presence of EXPAREL any more than they are
DRUG INTERACTIONS Patients with severe hepatic disease, because of their inability to metabolize by saline. None of the materials studied had an adverse effect on EXPAREL.
The toxic effects of local anesthetics are additive and their co-administration local anesthetics normally, are at a greater risk of developing toxic plasma Non-Interchangeability with Other Formulations of Bupivacaine
should be used with caution including monitoring for neurologic and cardio- concentrations, and potentially local anesthetic systemic toxicity. Therefore, Different formulations of bupivacaine are not bioequivalent even if the
vascular effects related to local anesthetic systemic toxicity. Avoid additional consider increased monitoring for local anesthetic systemic toxicity in subjects milligram dosage is the same. Therefore, it is not possible to convert dosing from
use of local anesthetics within 96 hours following administration of EXPAREL. with moderate to severe hepatic disease. any other formulations of bupivacaine to EXPAREL and vice versa.
Renal Impairment Liposomal encapsulation or incorporation in a lipid complex can substantially
Patients who are administered local anesthetics may be at increased risk of
developing methemoglobinemia when concurrently exposed to the following Bupivacaine is known to be substantially excreted by the kidney, and the risk affect a drug’s functional properties relative to those of the unencapsulated or
drugs, which could include other local anesthetics: of toxic reactions to this drug may be greater in patients with impaired renal nonlipid-associated drug. In addition, different liposomal or lipid-complexed
function. This should be considered when performing dose selection of EXPAREL. products with a common active ingredient may vary from one another in the
Examples of Drugs Associated with Methemoglobinemia: chemical composition and physical form of the lipid component. Such differences
OVERDOSAGE
Class Examples Clinical Presentation may affect functional properties of these drug products. Do not substitute.
Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Acute emergencies from local anesthetics are generally related to high plasma CLINICAL PHARMACOLOGY
concentrations encountered during therapeutic use of local anesthetics or to Pharmacokinetics
Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, unintended intravascular injection of local anesthetic solution.
mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Administration of EXPAREL results in significant systemic plasma levels of
Signs and symptoms of overdose include CNS symptoms (perioral paresthesia, bupivacaine which can persist for 96 hours after local infiltration and 120 hours
Antineoplastic cyclophosphamide, flutamide, hydroxyurea, ifosfamide, dizziness, dysarthria, confusion, mental obtundation, sensory and visual after interscalene brachial plexus nerve block. In general, peripheral nerve blocks
agents rasburicase disturbances and eventually convulsions) and cardiovascular effects (that range have shown systemic plasma levels of bupivacaine for extended duration when
Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, from hypertension and tachycardia to myocardial depression, hypotension, compared to local infiltration. Systemic plasma levels of bupivacaine following
sulfonamides bradycardia and asystole). administration of EXPAREL are not correlated with local efficacy.
Antimalarials chloroquine, primaquine Plasma levels of bupivacaine associated with toxicity can vary. Although PATIENT COUNSELING
concentrations of 2,500 to 4,000 ng/mL have been reported to elicit early Inform patients that use of local anesthetics may cause methemoglobinemia, a
Anticonvulsants Phenobarbital, phenytoin, sodium valproate subjective CNS symptoms of bupivacaine toxicity, symptoms of toxicity have serious condition that must be treated promptly. Advise patients or caregivers
Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine been reported at levels as low as 800 ng/mL. to seek immediate medical attention if they or someone in their care experience
Management of Local Anesthetic Overdose the following signs or symptoms: pale, gray, or blue colored skin (cyanosis);
Bupivacaine headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.
Bupivacaine HCl administered together with EXPAREL may impact the phar- At the first sign of change, oxygen should be administered.
macokinetic and/or physicochemical properties of EXPAREL, and this effect The first step in the management of convulsions, as well as underventilation or
is concentration dependent. Therefore, bupivacaine HCl and EXPAREL may be apnea, consists of immediate attention to the maintenance of a patent airway
administered simultaneously in the same syringe, and bupivacaine HCl may be and assisted or controlled ventilation with oxygen and a delivery system
injected immediately before EXPAREL as long as the ratio of the milligram dose capable of permitting immediate positive airway pressure by mask. Immediately
of bupivacaine HCl solution to EXPAREL does not exceed 1:2. after the institution of these ventilatory measures, the adequacy of the circula- Pacira Pharmaceuticals, Inc.
Non-bupivacaine Local Anesthetics tion should be evaluated, keeping in mind that drugs used to treat convulsions San Diego, CA 92121 USA
sometimes depress the circulation when administered intravenously. Should Patent Numbers:
EXPAREL should not be admixed with local anesthetics other than bupivacaine. convulsions persist despite adequate respiratory support, and if the status of
Nonbupivacaine based local anesthetics, including lidocaine, may cause an the circulation permits, small increments of an ultra-short acting barbiturate 6,132,766 5,891,467 5,766,627 8,182,835
immediate release of bupivacaine from EXPAREL if administered together (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may Trademark of Pacira Pharmaceuticals, Inc.
locally. The administration of EXPAREL may follow the administration of be administered intravenously. The clinician should be familiar, prior to the
lidocaine after a delay of 20 minutes or more. There are no data to support For additional information call 1-855-RX-EXPAREL (1-855-793-9727)
use of anesthetics, with these anticonvulsant drugs. Supportive treatment of Rx only November 2018
administration of other local anesthetics prior to administration of EXPAREL.CASA 2019 Board of Directors
OFFICERS
PRESIDENT Danny Bundren, CASC, CPA, JD Jessie Monnier, RN, MSN, MBA, CASC
Deborah J. Miller VP, Operations and Development Regional VP, USPI
Division VP Operations, AMSURG Administrator 2695 Townsend Court
645 E. Missouri Ave., Ste. 300 Specialty Surgical Centers of Beverly Hills Sacramento, CA 95864
Phoenix, AZ 85012 310 Seven Springs Way, Suite 500 Phone: 916-213-7874
Phone: 602-659-0108 Brentwood, Tennessee 37027 E-Mail: jmonnier@uspi.com
Email: dmiller@amsurg.com Phone: 615-234-7952 Term Expires: Dec. 2020
Term Expires: Dec. 2021 E-mail: DBundren@surgerypartners.com Education Chair
Term Expires: Dec. 2022
PRESIDENT ELECT Dr. Michael Stuntz
Michelle George RN, MSN, CASC Bill Davis Monterey Peninsula Surgery Center
VP, Professional Development ASC Consultant 966 Cass Street #210
Surgical Care Affiliates ASC Solutions Monterey, CA 9394
Phone: 209-385-3525 Phone: 916-715-1448 Phone: 831.521.3125
E-mail: michelle.george@scasurgery.com E-mail: bdavis@ascsolutions.org Email: mikestuntz@hotmail.com
Term Expires: Dec. 2021 Term Expires: Dec. 2021 Term Expires: Dec. 2022
Research Benchmarking Chair
Brad Heaton, CASC Randy Todorovich, RN, CASC
SECRETARY Regional Director of Operations Senior VP Managed Care
Trey Parsons Sutter Surgery Center Division Ambulatory Systems Development, LLC
VP of Operations 2880 Gateway Oaks, Ste 220 24353 Allegra Way
Ambulatory Systems Development, LLC Sacramento, CA 95833 Valencia, CA 91355
850 E. Ocean Blvd., Unit 901 Phone: 916-566-4907 Email: randyt@asd-asc.com
Long Beach, CA 90802 E-mail: heatonb@sutterhealth.org Term Expires: Dec. 2019
Phone: 760-710-1757 Term Expires: Dec. 2021 Health Plan Chair
Email: tparsons@asd-asc.com Membership Chair
Term Expires: Dec. 2022 Tara Vail
Federal Advocacy Chair Kian Karimi, MD, FACS Chief Operating Officer
Medical Director & Founder, HST ASC Software
TREASURER Rejuva Medical Aesthetics 3675 Mt. Diablo Blvd., Suite 100B
Tersa Lech Medical Director, CosmoFrance Inc. Lafayette, CA 94549
Consultant Medical Director, NovaThreads Inc. Phone: 925-282-1980
295 Fox Hills Drive 11645 Wilshire Blvd., Suite 605 E-Mail:tara.vail@hstpathways.com
Thousand Oaks, CA 91361 Los Angeles, CA 90025 Term Expires: Dec. 2022
Phone: 805-794-5823 Phone: 424-644-2400
Email: tersalech36@gmail.com E-mail:kiankarimi@gmail.com CASA ANCILLARY SERVICES
Term Expires: Dec. 2020 Term Expires: Dec. 2022 EXECUTIVE DIRECTOR
Finance Chair Ethics Chair Beth LaBouyer, RN, CNOR, CASC
PO Box 292698
IMMEDIATE PAST PRESIDENT Carrie Millsap Sacramento, CA 95829
Peggy Wellman Chief Operating Officer Phone: 530-790-7990
Market President, USPI Monterey Peninsula Surgery Centers LLC Fax: 530-790-7644
200 N. Westlake Blvd., Suite 104 966 Cass St. #150 E-mail: blabouyer@casurgery.org
Westlake Village, CA 91362 Monterey, CA 93940
Phone: 805-241-6764 Phone: 949-244-7772 LEGISLATIVE ADVOCATE
Email: pwellman@uspi.com E-Mail: cmillsap@mpscllc.org Bryce Docherty – KP Public Affairs
Term Expires: Dec. 2019 Term Expires: Dec. 2020 1201 K Street, Suite 800
Sacramento, California 95814
Phone: 916-448-2162
BOARD MEMBERS E-Mail: bdocherty@ka-pow.com
Administrative Support
Conference Manager
April Ligtenberg
PO Box 292698
Sacramento, CA 95829
2019 Conference Committee Deb Miller, Chairperson Phone: 916-594-9351
Cell: 714-330-2343
E-Mail: aligtenberg@casurgery.org
Rita Bowen Beth LaBouyer Jessie Monnier Vanessa Sindell
Christine Shea Lansberry Tito Perez Laura Stangrover Marketing & Member Services
Constable Tersa Lech Shellee Randol Kari Stewart Shellee Randol | Randol Graphics
Jennifer Fox April Ligtenberg Patty Robles Peggy Wellman PO Box 292698
Nate Garner Janette Lischeske Carmen Romoff Mary Whitmore Sacramento, CA 95829
Michelle George Alexandra Luckhardt Karen Roy Rita Williamson Phone: 209-384-1640
Fax: 844-273-8336
Charlene Goff Debbie Mack Shawndra Simpson
E-Mail: membership@casurgery.org
Lori Jerome Kristi McCarthy Tonyanika SimpsonYou can also read
